Apollo Therapeutics

Apollo Therapeutics is a portfolio biotech company that develops a pipeline of clinical-stage drug discovery programs to generate breakthrough discoveries and create value for investors, stakeholders and patients in high-value markets.

Apollo CEO Richard Mason. Credit – Apollo Therapeutics.

The biopharma team's ‘drug hunters’ and scientific experts are building an expansive and de-risked portfolio in oncology, major inflammatory disorders and rare diseases. Its assets portfolio currently features 20 biologically focused programs in immunology, cell signalling, cell stress response, and more.

Originally founded as a partnership between three world-renowned research universities, the University of Cambridge, Imperial College London, and UCL, and global pharmaceutical companies AstraZeneca, GSK and J&J in 2022, Apollo secured a further two high-profile research partners in Kings College London and the Institute of Cancer Research (which boasts over 800 scientists).

Apollo added $33.5m to its Series C round in January 2024 taking its haul to $260m. Apollo has operations in Cambridge UK, Boston and Chicago. Dr Richard Mason is Apollo Therapeutics’ CEO.

Newsdesk

news@businessweekly.co.uk